Cogstate (ASX:CGS) books US$89m of contracts and the H1 scare looks like noise

FY27 opens with US$48.3m already contracted, up 54%, and the second-half rebound thesis just landed

Cogstate Ltd (ASX:CGS) has just closed FY26 with US$89.0 million of net sales contracts executed, up 116% on the US$41.3 million booked in FY25. The June quarter alone delivered US$21.9 million, keeping the pace set across every quarter of the year.

The number that matters more sits below the headline. Contracted future revenue heading into FY27 now stands at US$118.5 million, a 32% lift on last year. Of that, US$48.3 million is expected to convert into recognised revenue during FY27, up 54% on the comparable position twelve months ago.

For readers who followed the 22% sell-off earlier this year when management flagged H1 timing delays, this update is the answer to the question the market refused to wait for. The demand was always there. The contracts kept getting signed.

Cogstate is a neuroscience endpoint company that provides digital cognitive testing and analytics to pharmaceutical customers running trials in Alzheimer’s, Parkinson’s and adjacent CNS conditions. When a drug developer needs to prove a therapy is actually improving cognition, Cogstate is one of the very few global specialists they call.

The 116% contract jump tells you demand never softened

Every quarter of FY26 delivered materially more contract value than the same quarter in FY25. Sep was up 88%, Dec up 128%, Mar up 263% and Jun up 57%. That is not a lumpy one-off, that is a business operating on a different demand curve.

The 116% full-year lift lands against a backdrop where CNS drug development, particularly in Alzheimer’s, has moved from a graveyard to a genuine growth market. Lecanemab and donanemab approvals have pulled biotech capital back into the space, and Cogstate sits directly in the trial workflow that funding pays for.

The read for investors is that the H1 FY26 wobble was genuinely about revenue recognition timing, not the pipeline drying up. Sales contracts are a leading indicator, recognised revenue lags. What was frustrating six months ago now looks like a mechanical delay working through a much bigger book.

US$48.3m already banked for FY27 reshapes the model

Cogstate is entering FY27 with US$48.3 million of Clinical Trials revenue already contracted for the current financial year, a 54% jump on the equivalent position last year. That gives management visibility on the bulk of the FY27 top line before a single new deal is signed.

The remaining US$70.2 million of contracted revenue sits in FY28 and beyond, up 20%. So the shape of the backlog is not just bigger, it is more front-loaded into the year that matters for the next earnings cycle.

We think the market has not fully priced this yet. A company that visibly grew its contracted forward book by 32% while the share price spent most of the last twelve months digesting a timing scare has room to re-rate if H1 FY27 lands cleanly.

What we will be watching at the 18 August result

Cogstate releases audited FY26 numbers on Tuesday 18 August 2026, with an investor call the same day covering FY27 priorities and capital allocation. Two things will matter more than the headline earnings figure.

First, gross margin recovery. H1 FY26 saw margins compress to 50 to 52% from 61% a year earlier as service-heavy contracts and pre-hire investment weighed on the mix. Second, the capital allocation plan management has flagged, which is a genuine tell on how the board is thinking about the balance sheet now that the contracted book has doubled.

The Investors Takeaway for Cogstate

The bull case on Cogstate always rested on the durability of CNS trial demand and the company’s grip on a niche most contract research organisations cannot easily replicate. Today’s numbers make that case harder to argue against. The bear case has narrowed to a question of margin recovery through FY27.

The 18 August result is the near-term catalyst that either confirms the re-rating thesis or extends the waiting game. Investors who bought the timing-not-demand argument during the H1 sell-off now have the receipts. For our earlier take on why the H1 reaction was overdone, readers can revisit our previous coverage at stocksdownunder.